Celcuity Inc. announced that the first patient has been dosed in its Phase 1b/2 study (CELC-G-201) evaluating gedatolisib in combination with Nubeqa® (darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). Gedatolisib, the company?s lead therapeutic candidate, is a potent, reversible dual inhibitor that selectively targets all Class 1 PI3K isoforms and mTORC1/2. In August 2023, Celcuity announced that it had entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa® (darolutamide) to Celcuity at no cost for the Phase 1b/2 trial.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.14 USD | +1.35% | -7.87% | +10.91% |
Mar. 29 | Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement | CI |
Mar. 28 | Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.91% | 485M | |
-2.62% | 103B | |
+1.50% | 95.28B | |
+1.46% | 22.15B | |
-15.73% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.18% | 13.68B | |
+33.58% | 12.17B |
- Stock Market
- Equities
- CELC Stock
- News Celcuity Inc.
- Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer